fus-phase-separation-neurodegeneration

FUS Phase Separation in Neurodegeneration

Overview

FUS Phase Separation in Neurodegeneration describes the molecular cascade from normal FUS RNA-binding protein function through liquid-liquid phase separation (LLPS) to pathological aggregation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS (Fused in Sarcoma, also known as TLS) is a member of the FET (FUS, EWS, TAF15) family of RNA-binding proteins crucial for RNA metabolism. Disease-causing mutations induce a liquid-to-solid phase transition that drives neurodegeneration.

This mechanism page comprehensively covers: (1) FUS domain architecture and normal function, (2) the biophysics of liquid-liquid phase separation, (3) stress granule dynamics, (4) pathogenic phase transitions, and (5) therapeutic targeting strategies.

FUS Domain Architecture

Protein Structure

FUS is a 526-amino acid RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. The protein contains several distinct domains[@law2010]:

N-terminal Low-Complexity Domain (LCD, residues 1-214):

• Prion-like domain enriched in glycine, glutamine, asparagine, tyrosine, and serine
• Contains multiple phosphorylation sites
• Drives liquid-liquid phase separation
• Contains the prion-like domain critical for aggregation

RNA Recognition Motifs (RRM1 and RRM2, residues 260-380):

• Classical RRM fold for RNA binding
• Recognize GU-rich sequence motifs
• Also contribute to protein-protein interactions

...

FUS Phase Separation in Neurodegeneration

Overview

FUS Phase Separation in Neurodegeneration describes the molecular cascade from normal FUS RNA-binding protein function through liquid-liquid phase separation (LLPS) to pathological aggregation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS (Fused in Sarcoma, also known as TLS) is a member of the FET (FUS, EWS, TAF15) family of RNA-binding proteins crucial for RNA metabolism. Disease-causing mutations induce a liquid-to-solid phase transition that drives neurodegeneration.

This mechanism page comprehensively covers: (1) FUS domain architecture and normal function, (2) the biophysics of liquid-liquid phase separation, (3) stress granule dynamics, (4) pathogenic phase transitions, and (5) therapeutic targeting strategies.

FUS Domain Architecture

Protein Structure

FUS is a 526-amino acid RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. The protein contains several distinct domains[@law2010]:

N-terminal Low-Complexity Domain (LCD, residues 1-214):

• Prion-like domain enriched in glycine, glutamine, asparagine, tyrosine, and serine
• Contains multiple phosphorylation sites
• Drives liquid-liquid phase separation
• Contains the prion-like domain critical for aggregation

RNA Recognition Motifs (RRM1 and RRM2, residues 260-380):

• Classical RRM fold for RNA binding
• Recognize GU-rich sequence motifs
• Also contribute to protein-protein interactions

Zinc Finger Domain (ZF, residues 382-421):

• Cys2His2-type zinc finger
• Enhances RNA binding
• Contributes to nuclear localization

C-terminal Nuclear Localization Signal (NLS, residues 498-526):

• PY motif (Pro-Tyr) for nuclear import
• Binds transportin-1 (karyopherin-β2)
• Site of multiple ALS-causing mutations

Normal FUS Function

Nuclear Functions

In the nucleus, FUS participates in essential RNA metabolism[@blasco2022]:

1. Transcriptional Regulation

• Interacts with RNA polymerase II
• Co-activates transcription
• Regulates gene expression programs

2. Alternative Splicing

• Binds to pre-mRNA transcripts
• Regulates splice site selection
• Particularly important for neuronal transcripts

3. RNA Processing

• mRNA 3'-end processing
• RNA transport from nucleus
• RNA stability regulation

4. DNA Damage Response

• Recruitment to DNA damage sites
• Facilitates repair machinery
• Links transcription to DNA repair

Cytoplasmic Functions

FUS also functions in the cytoplasm:

1. RNA Transport

• Localizes to neuronal processes
• Transports mRNAs to synapses
• Regulates local translation

2. Stress Response
-Incorporates into stress granules

• Participates in stress response
• Protects mRNAs during stress

Liquid-Liquid Phase Separation

Biophysical Mechanism

Liquid-liquid phase separation (LLPS) is a fundamental biophysical process by which proteins and nucleic acids form condensed liquid-like droplets without a membrane[@zhang2019]. FUS undergoes LLPS through its low-complexity domain:

1. Multivalent Interactions

• Multiple weak interaction sites in LCD
• π-π stacking between aromatic residues
• Cation-π interactions with RNA

2. RNA-Mediated Crosslinking

• FUS binding to RNA increases valency
• RNA acts as scaffolding
• Formaldehyde crosslinking enhances droplet formation

3. Concentration Dependence

• LLPS occurs above a threshold concentration
• In vitro: ~1-5 μM FUS
• Cellular concentration approaches this threshold

Regulation of Phase Separation

Normal LLPS is tightly regulated:

Physiological Regulators:

• Post-translational modifications (phosphorylation)
• RNA-to-protein ratio
• Molecular crowding
• Ionic conditions

Stress-Induced Changes:

• Stress triggers FUS relocalization
• SG components increase local concentration
• LLPS is enhanced

Stress Granule Dynamics

FUS in Stress Granules

FUS is a canonical stress granule component[@dormann2010]. Under stress conditions:

1. Recruitment to Stress Granules

• Stress triggers phosphorylation of eIF2α
• Global translation is attenuated
• FUS is recruited to SGs

2. Dynamic Exchange

• FUS freely exchanges in normal SGs
• Liquid-like behavior is maintained
• Return to normal upon stress resolution

3. Physiological Role

• Protects specific mRNAs
• Enables stress recovery
• Facilitates translation restart

Disease-Altered SG Dynamics

ALS-associated FUS mutations dramatically alter SG dynamics[@dormann2010]:

1. Enhanced SG Recruitment

• Mutant FUS shows increased SG partitioning
• Mutations accelerate recruitment
• More FUS is retained in SGs

2. Delayed Disassembly

• Mutant FUS delays SG dissolution
• SG persistence is prolonged
• Recovery from stress is impaired

3. Altered Material Properties

• Droplet viscosity is increased
• Dynamics are slowed
• Liquid-to-solid transition is favored

Pathogenic Phase Transitions

Liquid-to-Solid Transition

The critical pathogenic event is the liquid-to-solid phase transition induced by ALS mutations[@murakami2015]:

Molecular Mechanism:

• Mutations in the low-complexity domain
• Alteration of interaction surfaces
• Increased propensity for β-sheet formation
• Stable fibril formation

Key Mutations:

• P525L: Most aggressive, juvenile-onset
• R521C: Most common adult-onset
• R522G, R514P, R521H

Consequences:

• Loss of droplet dynamics
• Irreversible aggregation
• Sequestration of normal proteins

Amyloid Fibril Formation

Beyond gelation, FUS can form amyloid-like fibrils[@shenoy2023]:

Fibril Structure:

• Cross-β sheet architecture
• Similar to amyloid fibrils
• Detectable by cryo-EM

Template-Directed Aggregation:

• FUS fibrils can template normal FUS
• Prion-like propagation
• Intercellular spread

Nuclear Import Defects

Transportin-1 Mediated Import

The C-terminal NLS of FUS binds transportin-1 (also called karyopherin-β2) for nuclear import[@butta2020]:

Normal Import:

• FUS NLS binds transportin-1
• Cargo complex translocates through nuclear pore
• FUS enters the nucleus

Mutant Import:

• Most ALS mutations cluster in the NLS
• P525L disrupts transportin-1 binding
• Nuclear import is impaired

Cytoplasmic Accumulation

Impaired nuclear import leads to cytoplasmic accumulation:

Consequences:

• Cytoplasmic FUS is recruited to SGs
• Normal nuclear function is lost
• Cytoplasmic gain-of-function occurs

Therapeutic Target:
-Transportin-1 modulators

• Nuclear import enhancers

Therapeutic Targeting Strategies

Current Approaches

| Target | Strategy | Status |
|--------|----------|--------|
| FUS expression | ASO silencing | Preclinical |
| Phase separation | LLPS modulators | Research |
| Nuclear import | Transportin-1 modulators | Research |
| Aggregation | Small molecules | Preclinical |
| Clearance | Autophagy enhancers | Preclinical |
| Neuroprotection | Antioxidants, mitochondrial protectants | Preclinical |

Small Molecule Approaches

Phase Separation Modulators:

• Target LLPS dynamics
• Prevent liquid-to-solid transition
• Modulate viscosity

Aggregation Inhibitors:

• Prevent fibril formation
• Disrupt existing aggregates
• Promote clearance

Nuclear Import Enhancers:

• Increase transportin-1 function
• Enhance nuclear localization

Gene Therapy Approaches

ASO-Mediated Silencing:

• Reduce mutant FUS expression
• Allele-specific approaches possible
• Viral delivery under development

CRISPR-Based Editing:

• Correct mutations
• Allele-specific targeting
• Promising but in early stages

Autophagy Clearance

Selective Autophagy

FUS inclusions are cleared via selective autophagy:

p62/SQSTM1-Mediated:

• Recognizes ubiquitinated FUS
• Targets to autophagosomes
• Lysosomal degradation

OPTN-Mediated:

• OPTN serves as receptor
• TBK1 phosphorylates OPTN
• Both ALS-linked proteins

Therapeutic Enhancement

Autophagy enhancement promotes clearance:

• mTOR inhibitors (rapamycin, torin1)
• TFEB activators (trehalose)
• Autophagy gene therapy

Cross-Links

• [FUS Proteinopathy](/mechanisms/fus-proteinopathy)
• [Stress Granule Homeostasis in ALS/FTD](/mechanisms/stress-granule-homeostasis-als-ftd)
• [ALS FUS Pathway](/mechanisms/als-fus-pathway)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [Frontotemporal Dementia (FTD](/diseases/ftd)
• [Amyotrophic Lateral Sclerosis (ALS](/diseases/als)

Clinical Features of FUS-ALS

• Younger age of onset (often <40 years)
• Rapid progression
• Predominant bulbar involvement
• Prominent upper motor neuron signs
• Cognitive/behavioral changes in some cases

Biomarkers

• Neurofilament light chain (NfL): Elevated, disease progression
• FUS in CSF: Potential biomarker
• Genetic testing: Identifies pathogenic mutations
• Neuroimaging: Corticospinal tract abnormalities

References

[Law WJ, et al, TLS, FUS, EWS and TAF15: a novel group of nuclear RNA-binding proteins (2010)](https://doi.org/10.4161/rna.8.6.16621)

[Zhang L, et al, Role of the low complexity domain in FUS phase separation (2019)](https://doi.org/10.1126/science.aav4470)

[Murakami T, et al, ALS/FTD mutations induce a liquid-to-solid phase transition (2015)](https://doi.org/10.1016/j.neuron.2015.08.020)

[Dormann D, et al, ALS-associated FUS mutations disrupt stress granule dynamics (2010)](https://doi.org/10.1038/emboj.2010.254)

[Butler M, et al, FUS-mediated nuclear transport in ALS pathogenesis (2020)](https://doi.org/10.1038/s41582-020-0356-0)

[Gasset-Rosa F, et al, Targeting phase separation as therapeutic strategy in ALS/FTD (2024)](https://doi.org/10.1016/j.tins.2023.11.005)

[Houston BJ, et al, FUS is phosphorylated by DNA-dependent protein kinase (2018)](https://doi.org/10.1371/journal.pone.0201504)

[Sidhu H, et al, FUS, TDP-43 and the cellular stress response in ALS/FTD (2014)](https://doi.org/10.398/j.issn.1673-5374.2014.02.009)

[Blasco H, et al, FUS-regulated RNA metabolism in ALS pathogenesis (2022)](https://doi.org/10.1016/j.pnpbp.2022.110497)

[Shenoy J, et al, FUS aggregates: From liquid-liquid phase separation to amyloid fibrils (2023)](https://doi.org/10.1186/s40478-023-01487-0)

[Singh V, et al, FUS phase separation and aggregation in neurodegeneration (2024)](https://doi.org/10.1016/j.jmb.2024.168484)